摩根大通称 Biogen 因多项临床数据即将发布有望录得显著涨幅

1. 核心事实剥离

Biogen（BIIB）将在未来数月内集中披露多项在研管线的临床数据，摩根大通认为这一催化剂群应当推升其股价 〔SRC〕〔SRC:"Biogen will release data from clinical trials for a few of its investigational treatments over the next few months, which should boost its shar